The SciFinder tool lets you search Titles, Authors, and Abstracts of talks and panels. Enter your search term below and your results will be shown at the bottom of the page. You can also click on a track to see all the talks given in that track on that day.

View Talks By Category

Scroll down to view Results

July 12, 2024
July 13, 2024
July 14, 2024
July 15, 2024
July 16, 2024

Results

July 16, 2024
8:40-9:20
Invited Presentation: Advancing Genomic Medicine through Clinical and Research Strategies
Confirmed Presenter: Heidi Rehm
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Maria Secrier


Authors List: Show

  • Heidi Rehm

Presentation Overview:Show

Supporting genomics in research and medicine requires infrastructure, including standards, knowledgebases and global data sharing, as well as a rich interface between research and clinical care as new discoveries are made. This talk will present strategies to identify novel causes of rare disease including the application of new technologies and analysis methods as well as building innovative approaches to global data sharing in collaboration with AnVIL and the Global Alliance for Genomics and Health. It will end on novel approaches to support genetics and genomics in medical practice.

July 16, 2024
9:20-9:40
Transcriptional modulation unique to vulnerable motor neurons predict ALS across species and SOD1 gene mutations
Confirmed Presenter: Irene Mei, Department of Biochemistry and Biophysics, Stockholm University
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Maria Secrier


Authors List: Show

  • Irene Mei, Irene Mei, Department of Biochemistry and Biophysics
  • Susanne Nichterwitz, Susanne Nichterwitz, Department of Biochemistry and Biophysics
  • Melanie Leboeuf, Melanie Leboeuf, Department of Biochemistry and Biophysics
  • Jik Nijssen, Jik Nijssen, Department of Cellular and Molecular Biology
  • Isadora Lenoel, Isadora Lenoel, Institute de Cerveau (ICM)
  • Dirk Repsilber, Dirk Repsilber, School of Medical Sciences
  • Christian S. Lobsiger, Christian S. Lobsiger, Institute de Cerveau (ICM)
  • Eva Hedlund, Eva Hedlund, Department of Biochemistry and Biophysics

Presentation Overview:Show

Amyotrophic lateral sclerosis (ALS) is characterized by the progressive loss of somatic motor
neurons (MNs), which innervate skeletal muscles. However, certain MN groups including ocular MNs that regulate eye movement are relatively resilient to ALS. To reveal mechanisms of differential MN vulnerability, we investigate the transcriptional dynamics of two vulnerable and two resilient MN populations in SOD1G93A ALS mice. Differential gene expression analysis shows that each neuron type displays a largely unique spatial and temporal response to ALS. Resilient MNs regulate few genes in response to disease, but show clear divergence in baseline gene expression compared to vulnerable MNs, which in combination may hold the key to their resilience. EASE, fGSEA and ANUBIX enrichment analysis demonstrate that vulnerable MN groups share pathway activation, including regulation of neuronal death, ERK and MAPK cascades, inflammatory response and synaptic signaling. These pathways are largely driven by 11 upregulated genes, including Atf3, Cd44, Gadd45a, Ngfr, Ccl2, Ccl7, Gal, Timp1, Nupr1 and indicate that cell death occurs through similar mechanisms across vulnerable MNs albeit with distinct timing. Random Forest machine learning-based approach using DEGs upregulated in our SOD1G93A spinal MNs predict disease in human stem cell-derived MNs harboring the SOD1E100G mutation, and show that dysregulation of VGF, PENK, INA and NTS are strong disease-predictors across SOD1 mutations and species. A shared transcriptional vulnerability was also assessed through a meta-analysis across mouse SOD1 transcriptome datasets. In conclusion our study reveals vulnerability-specific gene regulation that may act to preserve neurons and can be used to predict disease.

July 16, 2024
9:20-9:40
Multi-dimensional Integration of PPI Network with Genetic and Molecular Data to Decipher the Genetic Underpinnings of RA Endotypes
Confirmed Presenter: Javad Rahimikollu, University of Pittsburgh, United States
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Maria Secrier


Authors List: Show

  • Javad Rahimikollu, Javad Rahimikollu, University of Pittsburgh
  • Priyamvada Guha Roy, Priyamvada Guha Roy, University of Pittsburgh
  • Larry Moreland, Larry Moreland, University of Colorado
  • Jishnu Das, Jishnu Das, University of Pittsburgh

Presentation Overview:Show

Rheumatoid arthritis (RA) is a complex autoimmune disease with polyetiological genetic basis. Serum rheumatoid factor (RF) and anti-citrullinated peptide (CCP) antibodies are used to diagnose RA. However, it is unknown whether corresponding serological profiles map to distinct endotypes of RA. To address this, we first dissected differences across ~900 RA patients half of whom were serologically CCP+RF+ (i.e., double positive – DP), and half that were RF+ alone (RF). Surprisingly, there was a significant difference in heritability across these groups (~30%), suggesting fundamental differences in genetic risk of these two kinds of RA. Next, we carried out a genome wide association analysis (GWAS) and identified the HLA locus as explaining part of but not the entire difference in heritability between DP and RF RA. To delve into the missing heritability, we implemented a network-based GWAS approach. We adapt Linkage Disequilibrium Adjusted Kinships (LDAK) to aggregate the impact of multiple regulatory SNPs associated with a gene into a single score, taking into account the underlying LD structure. Using network propagation, we then identify modules that explain significant the differences in heritability across DP and RF. These modules include HLA genes, but also capture other cytokines, chemokines and immune regulators and almost completely capture the entire difference in heritability. We were also able to further validate these modules by recapitulating some of the corresponding differences at the transcriptomic and proteomic level. Together, our results suggest that DP and RF RA are different disease endotypes with distinct genetic bases and pathophysiology.

July 16, 2024
9:40-10:00
AI Epilepsy: Software solution to aid in the diagnosis of epilepsy using machine learning algorithms
Confirmed Presenter: Juan Carvajal, Universidad de los Andes, Colombia
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Maria Secrier


Authors List: Show

  • Juan Carvajal, Juan Carvajal, Universidad de los Andes
  • Laura Guio, Laura Guio, HOMI
  • Danilo García-Orjuela, Danilo García-Orjuela, Biotecnología y Genética SAS
  • David Diaz, David Diaz, Universidad de los Andes
  • Diego Granada, Diego Granada, Universidad de los Andes
  • Andres Delgado Ruiz, Andres Delgado Ruiz, Universidad de los Andes
  • Nestor Gonzalez, Nestor Gonzalez, Universidad de los Andes
  • Jennifer Guzmán-Porras, Jennifer Guzmán-Porras, HOMI
  • Paula Siaucho, Paula Siaucho, Biotecnología y Genética SAS
  • Jorge Díaz-Riaño, Jorge Díaz-Riaño, Biotecnología y Genética SAS
  • Andres Naranjo, Andres Naranjo, HOMI
  • Silvia Maradei-Anaya, Silvia Maradei-Anaya, Biotecnología y Genética SAS
  • Jorge Duitama, Jorge Duitama, Universidad de los Andes
  • Kelly Garces, Kelly Garces, Universidad de los Andes

Presentation Overview:Show

Epilepsy is a chronic neurological disorder characterized by recurrent seizures, affecting approximately 50 million people worldwide. Different methods have been developed for efficient diagnosis, including prediction of cases requiring surgical intervention due to lack of effectiveness of drug-based treatments (known as refractory epilepsy). These methods include signal processing using electroencephalography (EEG), analysis of structural MRI, and expression of miRNA biomarkers in peripheral blood. Given the heterogeneity of this data, we developed a software solution to perform an integrated analysis of these data types, to aid diagnosis of epilepsy. Users can load the results of the different exams to generate a common report including the results of the different analyses. The analysis includes a machine learning approach for detection of seizures from EEG data. It also includes a classification model for brain structural anomalies from MRI data. Finally, it includes a classification module based on the expression patterns of blood miRNA data. The software follows a distributed architecture with five main components orchestrated through docker compose. It facilitates the execution of asynchronous processes to run complex predictions by implementing Rabbit message queues. A visualzer of MRI scans was integrated for visualization and interaction with the data obtained from these images. Validation experiments show that the application is efficient and easy to use, taking into account the size and complexity of the data that needs to be analyzed together for epilepsy patients. We expect that this software makes a significant contribution towards the development of new tools and methods for epilepsy research.

July 16, 2024
9:40-10:00
HTJ2K as a Default Storage Format for Medical Images​
Confirmed Presenter: Utkarsh Rai, University of Arkansas for Medical Sciences, United States
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Maria Secrier


Authors List: Show

  • Utkarsh Rai, Utkarsh Rai, University of Arkansas for Medical Sciences
  • Lawrence Tarbox, Lawrence Tarbox, University of Arkansas for Medical Sciences
  • Chris Hafey, Chris Hafey, AWS HealthImaging

Presentation Overview:Show

Healthcare systems around the world store large volumes of medical images, like X-rays or scans. The largest public archive currently has 30.9 million radiology images. These images are high quality and use a lot of space making them difficult to store and share.​
Image compression comes with two main challenges, loss in the quality of the image and additional resources needed to compress currently existing images. My project proposes using a recently introduced image format, high-throughput JPEG 2000 (HTJ2K), for lossless compression of these images and bringing their size down by a rough factor of 3.​
This new format allows you to see a blurry version first which gradually gets clearer. This is very handy when you are dealing with slow internet or huge files. A single image file holds several copies of gradually improving resolutions and medical researchers can pick from any of these, without having to duplicate their datasets.​
My project provides open-source tools to convert medical images to HTJ2K, methods for users of the images to decode, view and use them as necessary and pipelines that system architects can use to model medical image storage using HTJ2K format such that they are easy to maintain.​

July 16, 2024
10:40-11:20
Invited Presentation: The challenges of clinical deployment of automated cancer type classification for routine use
Confirmed Presenter: Quaid Morris, Memorial Sloan Kettering Cancer Center, United States
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Irene Ong


Authors List: Show

  • Quaid Morris, Quaid Morris, Memorial Sloan Kettering Cancer Center
  • Madison Darmofal, Madison Darmofal, Memorial Sloan Kettering Cancer Center
  • Michael Berger, Michael Berger, Memorial Sloan Kettering Cancer Center

Presentation Overview:Show

Accurate cancer type classifiers would have profound impact on the success of cancer treatment. Each year, in the US, more than 30,000 people present with new cancers of unknown primary (CUP), for which treatment options are very limited. Up to half of these patients could be matched with FDA-approved therapies if their cancer type were known. Cancer type classifiers can also distinguish new cancers from reoccurrences and resolve difficult diagnostic challenges. We recently deployed a highly accurate cancer type classifier, GDD-ENS, at Memorial Sloan Kettering Cancer Center (MSKCC) based on inputs derived from an FDA-approved, and routinely applied, targeted DNA sequencing panel called MSK-IMPACT. GDD-ENS, based on ENSembles of multilayer perceptrons, and replaced a pre-existing MSKCC system, GDD-RF. To make GDD-ENS well-suited to the clinical setting, based on lessons learned from GDD-RF, we made specific design choice in the classifier, in its training and evaluation, and how its outputs are integrated with other routinely available clinical data. I will present GDD-ENS, these choices and their impacts, as well as, GDD-ENS’ successes and some areas of improvement. I will also discuss our efforts to generalize GDD-ENS to other targeted cancer gene panels.
Joint work with Dr Michael Berger and our labs.

July 16, 2024
11:20-11:40
CIViC - an open-access knowledgebase for community driven curation of clinical variants in cancer
Confirmed Presenter: Mariam Khanfar, Department of Medicine, Washington University School of Medicine
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Irene Ong


Authors List: Show

  • Mariam Khanfar, Mariam Khanfar, Department of Medicine
  • Susanna Kiwala, Susanna Kiwala, Department of Medicine
  • Kilannin Krysiak, Kilannin Krysiak, Department of Pathology and Immunology
  • Adam C. Coffman, Adam C. Coffman, Department of Medicine
  • Joshua F. McMichael, Joshua F. McMichael, McDonnell Genome Institute
  • Arpad M. Danos, Arpad M. Danos, Department of Medicine
  • Jason Saliba, Jason Saliba, Department of Medicine
  • Nilan Patel, Nilan Patel, Department of Medicine

Presentation Overview:Show

In the era of personalized oncology, identifying clinically relevant variants is critical due to the rapidly increasing variant data and need for consensus variant interpretation. The Clinical Interpretation of Variants in Cancer (CIViC-www.civicdb.org) knowledgebase is a free, open-access, open-source, and open-license public resource with an intuitive user interface and flexible public API for programmatic access to all content.

CIViC supports variant interpretations with six evidence types: Predictive (Therapeutic response), Diagnostic, Prognostic, Predisposing, Oncogenic, and Functional. The model also supports curating Molecular Profiles, which allows users to logically associate one or more variants with evidence. This expansion into ""Complex"" multi-variant profiles enables the evaluation of clinical significance in contexts such as variant co-occurrence or mutual exclusivity, further enhancing the utility of CIViC in the field of oncology.

All content in CIViC adheres to a structured data model which follows a published standard operating procedure for curation. This data model incorporates ontologies, standards and guidelines from across the field to promote interoperability and compatibility with other efforts. The CIViC community currently has >350 contributors that have generated >10,000 evidence items from >3,600 sources spanning >390 diseases and >530 therapies.

CIViC's key role in cancer variant interpretation was recognized with its inclusion in the list of 37 Global Core Biodata Resources, underscoring its value to the biological and life sciences community. As CIViC continues to adhere to rigorous standards in maintaining data quality, it remains an invaluable, freely accessible resource, advancing the field of personalized oncology.

July 16, 2024
11:20-11:40
Timing the development of chemoresistance in relapsed pediatric cancer
Confirmed Presenter: Sasha Blay, The Hospital for Sick Children, Canada
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Irene Ong


Authors List: Show

  • Sasha Blay, Sasha Blay, The Hospital for Sick Children
  • Mehdi Layeghifard, Mehdi Layeghifard, The Hospital for Sick Children
  • Scott Davidson, Scott Davidson, The Hospital for Sick Children
  • David Chen, David Chen, The Hospital for Sick Children
  • Astra Schwertschkow, Astra Schwertschkow, The Hospital for Sick Children
  • Vijay Ramaswamy, Vijay Ramaswamy, The Hospital for Sick Children
  • Michael Taylor, Michael Taylor, The Hospital for Sick Children
  • Elli Papaemmanuil, Elli Papaemmanuil, Memorial Sloan Kettering Cancer Center
  • Anita Villani, Anita Villani, The Hospital for Sick Children
  • David Malkin, David Malkin, The Hospital for Sick Children
  • Ludmil Alexandrov, Ludmil Alexandrov, University of California San Diego
  • Mark Cowley, Mark Cowley, Children's Cancer Institute
  • Adam Shlien, Adam Shlien, The Hospital for Sick Children

Presentation Overview:Show

Survivors of pediatric cancer face lifelong battles with severe morbidities, including a significant risk of recurrence. Mutational signatures are patterns of somatic mutations in the cancer genome with specific etiologies. Recent cell line work links mutational signatures to chemotherapy response, signifying chemoresistance. The Shlien lab has identified therapy-associated mutational signatures in the genomes of relapsed pediatric patients, creating an opportunity to characterise when and where the effects of chemotherapy are felt in the pediatric cancer genome. I thus developed a pipeline that combines clonal evolution reconstruction with mutational signature extraction to elucidate changes in mutational processes. I used this pipeline to analyze 1,743 pediatric tumor genomes from 10 pediatric cancer datasets. I detected mutational signatures linked to 4 chemotherapy drugs: temozolomide, platinum-based agents, fluorouracil, and thiopurine. Of 235 samples with confirmed exposure, 37.9% displayed one or more therapy-associated signatures. Mutational signatures associated with alkylating agents like cisplatin were more prevalent and mutationally heavy than those linked to antimetabolites, suggesting the drug mechanism dictates its presentation in the genome. I identified specific subclones with chemotherapy signatures, demarking subclone-level resistance. In cases with multiple tumour samples, resistant subclones in recurrences were traced back to ancestors in the primary diagnostic tumors, suggesting certain lineages possessed the ability to withstand chemotherapy-induced pressures from an early stage and then expanded following treatment. Thus, investigating mutational signatures at the subclonal level unveils new insights into the clonal dynamics of pediatric cancers and the development of chemoresistance.

July 16, 2024
11:40-12:00
PHENO-DEX: Phenotypic Mapping of Dexamethasone Response in Breast Cancer Cells using Single-cell Transcriptomics
Confirmed Presenter: Jiaqi Li, NIH, United States
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Irene Ong


Authors List: Show

  • Jiaqi Li, Jiaqi Li, NIH
  • Benedict Anchang, Benedict Anchang, NIH

Presentation Overview:Show

Identifying tumor heterogeneity in response to treatment prior to clinical intervention is critical for long-term survival. We’ve developed an AI-based reference mapping strategy to profile tumor subpopulations in response to perturbations using single-cell transcriptomics. This strategy, known as PHENO-DEX, integrates two major algorithms: DSFMix and PHENOSTAMP. We use DSFMix, based on tree models to identify response/non-response cell trajectories from a Dex-treated breast cancer cell dataset. Then, using a feed forward loop neural network algorithm, PHENOSTAMP, we next create a Dex-responding reference map, identifying 9 cell states (4 responsive and 5 non-responsive). Each cell state exhibits unique characteristics which correlates with cell plasticity response to Dex. We projected thirty breast cancer cell lines and three clinical breast cancer tumors onto the reference map, effectively revealing their cell state heterogeneity in response to Dex. In summary, we’ve provided a framework to comprehensively characterize both cell lines and clinical samples, which better dissects the responsive states to Dex of tumors prior to any treatment, thereby providing clinical guidance for treatment decisions.

July 16, 2024
11:40-12:00
Spatial landscape of malignant pleural and peritoneal mesothelioma tumor immune microenvironment
Confirmed Presenter: Hatice Osmanbeyoglu, University of Pittsburgh, United States
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Irene Ong


Authors List: Show

  • Xiaojun Ma, Xiaojun Ma, University of Pittsburgh
  • David Lembersky, David Lembersky, University of Pittsburgh
  • Elena Kim, Elena Kim, University of Pittsburgh
  • Joseph Testa, Joseph Testa, Fox Chase Cancer Center
  • Tullia Bruno, Tullia Bruno, University of Pittsburgh/Hillman Cancer Center
  • Hatice Osmanbeyoglu, Hatice Osmanbeyoglu, University of Pittsburgh

Presentation Overview:Show

Immunotherapies have shown modest clinical benefit thus far for malignant mesothelioma (MM). A deeper understanding of immune cell spatial distribution within the tumor immune microenvironment (TIME) is needed to identify interactions between tumor and different immune cell types that might impact the effectiveness of potential immunotherapies. We performed multiplex immunofluorescence (mIF) using tissue microarrays (TMAs, n=3) of samples from patients with malignant peritoneal (n=25) and pleural (n=88) mesothelioma (MPeM and MPM, respectively) to elucidate the spatial distributions of major immune cell populations and their association with LAG3, BAP1, NF2, and MTAP expression, the latter as a proxy for CDKN2A/B. We also analyzed the relationship between the spatial distribution of major immune cell types with MM patient prognosis and clinical features. The distribution of immune cells within the TIME is similar between MPM and MPeM. However, there is a higher level of interaction between immune cells and tumor cells in MPM than MPeM. Within MPM tumors, there is increased amount of interaction between tumor cells and CD8+ T cells in BAP1-low than in BAP1-high expressing tumors. The cell-cell interactions identified in this investigation have potential implications for the immune response against MM tumors and could be a factor in the different behaviors of MPM and MPeM. Our findings provide a valuable resource for the MM cancer research community and exemplifies the utility of spatial resolution within single-cell analyses. Our mesothelioma spatial atlas mIF dataset is available at
https://mesotheliomaspatialatlas.streamlit.app/.

July 16, 2024
12:00-12:20
Poster Flash Talks
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Irene Ong


Authors List: Show

July 16, 2024
14:20-14:40
Integrative transcriptomic analysis and predictive modeling for immunotherapy response in melanoma
Confirmed Presenter: Yamil Damian Mahmoud, Laboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Irene Ong


Authors List: Show

  • Yamil Damian Mahmoud, Yamil Damian Mahmoud, Laboratorio de Glicomedicina
  • Florencia Veigas, Florencia Veigas, Laboratorio de Glicomedicina
  • Marcelo Hill, Marcelo Hill, Laboratory of Immunoregulation and Inflammation
  • Maria Romina Girotti, Maria Romina Girotti, Laboratorio de Glicomedicina
  • Juan Manuel Perez-Saez, Juan Manuel Perez-Saez, Laboratorio de Glicomedicina
  • Gabriel A Rabinovich, Gabriel A Rabinovich, Laboratorio de Glicomedicina

Presentation Overview:Show

Despite significant advances in immunotherapies, a substantial subset of melanoma patients remains unresponsive, emphasizing the critical need for predictive biomarkers. Our study integrates transcriptomic analysis and predictive modeling to address this challenge.
We analyzed public single-cell RNASeq (scRNA-Seq) data from 48 melanoma biopsies (16,291 cells) and bulk RNASeq data from 514 patients treated with anti-PD1/anti-CTLA4. Non-responders exhibited upregulated glycosylation-related genes in macrophages and CD8 T-cells, indicative of compromised immune function. Additionally, macrophages from non-responder biopsies displayed an immunosuppressive profile, coinciding with a treatment-resistant cell sub-group.
Furthermore, we integrated scRNA-Seq data from various cancers (totaling 382,019 cells) and developed a signature for immune cell deconvolution in bulk datasets. Responders during treatment showed higher levels of CD8 T-cells, CD4 activated memory T-cells, and total immune infiltrate. Interestingly, responders also displayed increased levels of progenitor and terminally exhausted CD8 T cells compared to non-responders pre- and during treatment, respectively.
To create a robust predictive model of response to immunotherapies in melanoma, we combined the estimated immune cell composition with glycosylation-related genes, our previously published inflammasome pathway signature, and other known indicators, including tertiary lymphoid structures, cytolytic score, and PDL1 expression. Our XGBoost-based machine learning model was trained on the bulk RNA cohort data and achieved an accuracy of 0.79 and AUC of 0.87 with cross-validation.
In conclusion, our findings underscore the potential of integrating transcriptomic analysis and predictive modeling in translational medicine for predicting immunotherapy response in melanoma patients. This emphasizes the critical role of multi-omic approaches in precision medicine for cancer immunotherapy.

July 16, 2024
14:20-14:40
A computational approach for the high-throughput identification of cancer-specific antigens for immunotherapeutic development
Confirmed Presenter: Rawan Shraim, Children's Hospital of Philadelphia/Drexel University, United States
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Irene Ong


Authors List: Show

  • Rawan Shraim, Rawan Shraim, Children's Hospital of Philadelphia/Drexel University
  • Brian Mooney, Brian Mooney, BC Cancer Research Institute
  • Karina L. Conkrite, Karina L. Conkrite, Children's Hospital of Philadelphia
  • Amber K. Weiner, Amber K. Weiner, Children's Hospital of Philadelphia
  • Gregg B. Morin, Gregg B. Morin, BC Cancer Research Institute
  • Poul H. Sorensen, Poul H. Sorensen, BC Cancer Research Institute
  • John M. Maris, John M. Maris, Children's Hospital of Philadelphia
  • Sharon J. Diskin, Sharon J. Diskin, Children's Hospital of Philadelphia
  • Ahmet Sacan, Ahmet Sacan, Drexel University

Presentation Overview:Show

Cancer remains a major global health challenge, with current treatments such as chemotherapy and radiotherapy often limited by toxicity and late effects. This has prompted the development of targeted immunotherapies. An obstacle to the development of these therapies is the identification of cancer-specific antigens as therapeutic targets.

To address this challenge computationally, we developed a tool that prioritizes potential immunotherapeutic targets by integrating multi-source data, including user-supplied cancer expression data (e.g., proteomics or RNA-sequencing) and quantitative features from various databases selected to address a predefined criteria for ideal immunotherapeutic targets. Our tool can adjust for normalization, missing values, and applies feature weighting, producing a gene-specific score that reflects its suitability as a therapeutic target. We evaluated our tool’s performance using mean-average-precision (MAP) score, which assesses the prioritization rankings of known therapeutic targets within the cancer phenotype. Utilizing twelve pediatric cancer cell line proteomics datasets for validation of our methodology, we generated optimized parameters leading to a 27-fold increase (p < 0.001) in the MAP score, highlighting our tools’ target prioritization capabilities. Using the generated optimized parameters, our tool was able to score known chimeric antigen receptor T-cell targets such as CD19, CD22, CD79b in the top 10 targets in B-cell non-Hodgkin’s lymphoma, validating our methodology. Additionally, HLA-G was identified as a novel potential target across pediatric cancer phenotypes surveyed in the analysis.

We have developed a tool to efficiently identify immunotherapeutic targets that can be used to accelerate the development of safer and more effective cancer immunotherapies.

July 16, 2024
14:40-15:00
Leveraging a Single-Cell Language Model for Precise EMT Status Prediction and Gene Signature Identification in Cancer
Confirmed Presenter: Shi Pan, University college london, United Kingdom
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Sikander Hayat


Authors List: Show

  • Shi Pan, Shi Pan, University college london
  • Maria Secrier, Maria Secrier, University College London

Presentation Overview:Show

The epithelial-to-mesenchymal transition (EMT) is pivotal in tumour progression and resistance to treatment, yet its heterogeneity complicates the precise assessment of EMT status of individual tumour cells. While key epithelial and mesenchymal genes driving the transformation are well characterised, other regulators, especially at intermediate stages of the process, are less well understood.
By leveraging a pre-trained single-cell language model, we develop a generalisable classifier named EMT-language model (EMT-LM) to predict multiple states within the EMT continuum at single cell resolution. Our training data use an RNA-seq dataset from Cook et al [1], which profile single cells from 0 hours to 7 days during EMT. EMT-LM demonstrates an average prediction accuracy of EMT state of 90% AUROC across various cancers. Our Attention-Driven Expression Significance Index (ADESI) combines attention scores from EMT-LM and the gene expression, to uncover genes that are critical in regulating the entire timeline of EMT. Our top regulators include genes involved in mitochondrial function (e.g., NDUFB10, MRPL51) and oxidative stress response (e.g., PRDX1) suggesting a metabolic reprogramming during EMT. And patients exhibiting the 8h and 3d EMT signatures, as identified by genes with high attention scores in these categories, showed a notable decrease in survival rates in the METABRIC dataset.
In conclusion, EMT-LM exemplifies the effective application of language models in cancer biology research, offering a novel approach to EMT status prediction and identifying clinically relevant gene signatures reflecting the plasticity of the EMT programme.

July 16, 2024
14:40-15:00
Streamlining Clinical Trial Matching Using a Two-Stage Zero-Shot LLM with Advanced Prompting
Confirmed Presenter: Mozhgan Saeidi, Stanford University and Gladstone Institute, United States
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Sikander Hayat


Authors List: Show

  • Mozhgan Saeidi, Mozhgan Saeidi, Stanford University and Gladstone Institute
  • Barbara Engelhardt, Barbara Engelhardt, Gladstone Institute and Stanford University

Presentation Overview:Show

Identifying patients eligible for clinical trials is a critical bottleneck hindering medical research progress because many clinical trials allow only small, specific patient cohorts to be included in the clinical trial and require a certain number of participating patients to yield definitive results. Manually screening patients through unstructured medical records is time-consuming and expensive. This paper explores the potential of large language models (LLMs) enhanced with medical context to automate patient eligibility assessment for clinical trials. We first designed a two-stage zero-shot LLM approach to analyze a patient’s medical history (presented as unstructured text) to determine their eligibility for a given trial. We use advanced prompting strategies to guide the LLM toward faster and more targeted assessments. Additionally, a two-stage retrieval pipeline pre-filters potential trials using efficient retrieval techniques, reducing the number of trials considered by the LLM. This substantially improves processing speed and efficiency. Our method holds promise for streamlining clinical trial patient matching.

July 16, 2024
15:00-15:20
Multi-Omics Integration with High-Resolution AI-Derived Retinal Thickness: Unraveling Spatial Patterns of Retinal Susceptibility to Systemic Influences
Confirmed Presenter: Roberto Bonelli, The Lowy Medical Research Institute, United States
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Sikander Hayat


Authors List: Show

  • Roberto Bonelli, Roberto Bonelli, The Lowy Medical Research Institute
  • Victoria Jackson, Victoria Jackson, Population Health and Immunity Division
  • Yue Wu, Yue Wu, Department of Ophthalmology
  • Julia Owen, Julia Owen, Department of Ophthalmology
  • Samaneh Farashi, Samaneh Farashi, Population Health and Immunity Division
  • Yuka Kihara, Yuka Kihara, Department of Ophthalmology
  • Marin Gantner, Marin Gantner, The Lowy Medical Research Institute
  • Catherine Egan, Catherine Egan, Moorfields Eye Hospital NHS Foundation Trust
  • Katie Williams, Katie Williams, Moorfields Eye Hospital NHS Foundation Trust
  • Brendan Ansell, Brendan Ansell, Population Health and Immunity Division
  • Adnan Tufail, Adnan Tufail, Moorfields Eye Hospital NHS Foundation Trust
  • Aaron Lee, Aaron Lee, Department of Ophthalmology

Presentation Overview:Show

Retinal thickness is a marker of retinal health and more broadly, a promising biomarker for many systemic diseases. We processed the UK Biobank retinal OCT images using a convolutional neural network on more than 40,000 individuals to produce fine-scale retinal thickness measurements on >29,000 points in the macula, the part of the retina responsible for human central vision. We then performed a multi-omics analysis and tested the association of common genomic variants, metabolomic, blood and immune biomarkers, ICD10 codes and polygenic risk scores with each of the fine-scale macular thickness points. Our analysis reveals high-resolution spatial retinal thickness association with hundreds of genetic loci, metabolites with spatially clustered effects, systemic disorders such as multiple sclerosis affecting specific areas as well as blood biomarkers such as reticulocyte count correlating with strong retinal thinning. Using enrichment analysis, we highlight that the parafoveal region of the macula is particularly susceptible to systemic insults and that metabolic correlations with its thickness magnify with age. Together, these results demonstrate not only the exquisite susceptibility of the retina to molecular and phenotypic changes but also the gains in spatial discovery power and resolution achievable by integrating multi-omics datasets with AI-generated data. All our results are accessible through a bespoke web interface.

July 16, 2024
15:20-15:40
New methods to discover drug combinations impacting cancer incidence
Confirmed Presenter: Rachel Melamed, UMass lowell, United States
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Sikander Hayat


Authors List: Show

  • Panagiotis Nikolaos Lalagkas, Panagiotis Nikolaos Lalagkas, University of Massachusetts Lowell
  • Rachel Melamed, Rachel Melamed, UMass lowell

Presentation Overview:Show

In this work we seek to mine health claims data to find combinations of drugs that may alter onset of cancer. This work has an ultimate goal of preventing cancer related to medical treatment, and of suggesting new treatments for the disease. Because drug combinations impacting cancer are unlikely to be discovered using randomized trials, we develop new methods using observational data to discover these effects. Our novel method based on the marginal structural model, but also includes a number of evaluations to identify robust signals.

July 16, 2024
15:20-15:40
Closing Remarks
Track: TransMed

Room: 519
Format: In Person
Moderator(s): Sikander Hayat


Authors List: Show

  • TransMed Organizers